|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
ENTRADA THERAPEUTICS, INC. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
(CUSIP Number) |
Ansbert Gadicke c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100 Boston, MA, 02116 617-425-9200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
09/08/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2014, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,764,167.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2014 (B), L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
117,667.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM Asset Management Investors BV2014 LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
60,722.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2014 GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,881,834.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.8 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2014 LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,942,556.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BIOVENTURES 2018, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,810,592.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.7 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BIOVENTURES 2018 (B), L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
96,232.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
35,735.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.1 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2018 GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,906,824.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
MPM BioVentures 2018 LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,942,559.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
ANSBERT GADICKE | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
3,885,115.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
LUKE EVNIN | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
3,885,115.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Todd Foley | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
3,885,115.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock | |
| (b) | Name of Issuer:
ENTRADA THERAPEUTICS, INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON,
MASSACHUSETTS
, 02210. | |
Item 1 Comment:
Explanatory Note: This Amendment No. 1 to Schedule 13D ("Amendment No. 1") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Entrada Therapeutics, Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on November 12, 2021 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons.
Items 2, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 1 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.
| ||
| Item 2. | Identity and Background | |
| (a) | The entities and persons filing this statement are MPM BioVentures 2014, L.P. ("BV 2014"), MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), MPM Asset Management Investors BV2014 LLC ("AM BV2014 LLC"), MPM BioVentures 2018, L.P. ("BV 2018"), MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), MPM Asset Management Investors BV2018 LLC ("AM BV2018 LLC"), MPM BioVentures 2014 GP LLC ("BV 2014 GP"), MPM BioVentures 2014 LLC ("BV 2014 LLC"), MPM BioVentures 2018 GP LLC ("BV 2018 GP") and MPM BioVentures 2018 LLC ("BV 2018 LLC") (collectively, the "MPM Entities") and Ansbert Gadicke, Luke Evnin and Todd Foley (collectively, the "Listed Persons" and together with the MPM Entities, the "Filing Persons"). | |
| (b) | The address of the principal place of business for each of the MPM Entities and Ansbert Gadicke, Luke Evnin and Todd Foley is 399 Boylston Street, Boston, MA 02116. | |
| (c) | The principal business of each of the Filing Persons is the venture capital investment business. | |
| (d) | During the last five years, none of the Filing Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). | |
| (e) | During the last five years, none of the Filing Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. | |
| (f) | Each of the Listed Persons is a United States citizen and each of the MPM Entities is a Delaware limited partnership or limited liability company.
In accordance with the provisions of General Instruction C to Schedule 13D, information concerning the managers and each other person controlling the general partners of the MPM Entities required by Item 2 of Schedule 13D is listed on Schedule 1 hereto and is incorporated by reference herein. | |
| Item 5. | Interest in Securities of the Issuer | |
| (a) | See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 1 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. Drs. Gadicke and Evnin and Mr. Foley beneficially own 9.98% of the Common Stock as of the date of this filing, and due to field limitations of the SEC's EDGAR filing system, the percentages in row 11 for each of these Reporting Persons has been rounded to 9.9%.
The Common Stock is held as follows:
* 1,764,167 shares are held directly by BV 2014;
* 117,667 shares are held directly by BV 2014(B);
* 60,722 shares are held directly by AM BV2014 LLC;
* 1,810,592 shares are held directly by BV 2018;
* 96,232 shares are held directly by BV 2018(B); and
* 35,735 shares are held directly by AM BV2018 LLC.
BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B).
BV 2014 LLC is the manager of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC.
BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2018 and BV 2018(B).
BV 2018 LLC is the manager of AM BV2018 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2018 LLC.
Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and BV 2018 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B) and AM BV2018 LLC.
Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 38,936,669 Common Stock outstanding as of July 31, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on August 5, 2026.
| |
| (b) | See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 1 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. | |
| (c) | Except as set forth in Exhibit 99.2, the Reporting Persons have not effected any transactions in the Common Stock in the sixty days preceding the date of this filing. | |
| (d) | Inapplicable. | |
| (e) | Inapplicable. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 1 Schedule I
Exhibit 99.1 Joint Filing Statement
Exhibit 99.2 Trade Details | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule I
General Partners/Members
Ansbert Gadicke
c/o MPM BioImpact LLC
399 Boylston Street
Boston, MA 02116
Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.
Citizenship: USA
Luke Evnin
c/o MPM BioImpact LLC
399 Boylston Street
Boston, MA 02116
Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.
Citizenship: USA
Todd Foley
c/o MPM BioImpact LLC
399 Boylston Street
Boston, MA 02116
Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.
Citizenship: USA
Joint Filing Statement
I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Entrada Therapeutics, Inc. is filed on behalf of each of the undersigned.
Date: September 10, 2026 |
|
|
MPM BIOVENTURES 2014, L.P. |
| ||||||||
| |||||||||
By: |
| MPM BioVentures 2014 GP LLC, its General Partner |
| ||||||
By: |
| MPM BioVentures 2014 LLC, Its Managing Member |
| ||||||
| |||||||||
By: |
| /s/ Ansbert Gadicke |
| ||||||
Name: |
| Ansbert Gadicke |
| ||||||
Title: |
| Managing Director |
| ||||||
| |||||||||
MPM BIOVENTURES 2014 (B), L.P. |
| ||||||||
| |||||||||
By: |
| MPM BioVentures 2014 GP LLC, its General Partner |
| ||||||
By: |
| MPM BioVentures 2014 LLC, Its Managing Member |
| ||||||
| |||||||||
By: |
| /s/ Ansbert Gadicke |
| ||||||
Name: |
| Ansbert Gadicke |
| ||||||
Title: |
| Managing Director |
| ||||||
| |||||||||
MPM ASSET MANAGEMENT INVESTORS BV 2014 LLC |
| ||||||||
| |||||||||
By: |
| MPM BioVentures 2014 LLC, Its Manager |
| ||||||
| |||||||||
By: |
| /s/ Ansbert Gadicke |
| ||||||
Name: |
| Ansbert Gadicke |
| ||||||
Title: |
| Managing Director |
| ||||||
| |||||||||
MPM BIOVENTURES 2014 GP, LLC |
| ||||||||
| |||||||||
By: |
| MPM BioVentures 2014 LLC, Its Managing Member |
| ||||||
| |||||||||
By: |
| /s/ Ansbert Gadicke |
| ||||||
Name: |
| Ansbert Gadicke |
| ||||||
Title: |
| Managing Director |
| ||||||
MPM BIOVENTURES 2014 LLC | ||
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
MPM BIOVENTURES 2018, L.P. | ||
By: |
| MPM BioVentures 2018 GP LLC, its General Partner |
By: |
| MPM BioVentures 2018 LLC, Its Managing Member |
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
MPM BIOVENTURES 2018 (B), L.P. | ||
By: |
| MPM BioVentures 2018 GP LLC, its General Partner |
By: |
| MPM BioVentures 2018 LLC, Its Managing Member |
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
MPM ASSET MANAGEMENT INVESTORS BV 2018 LLC | ||
By: |
| MPM BioVentures 2018 LLC, Its Manager |
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
MPM BIOVENTURES 2018 GP, LLC | ||
By: |
| MPM BioVentures 2018 LLC, Its Managing Member |
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
| ||
MPM BIOVENTURES 2018 LLC | ||
By: |
| /s/ Ansbert Gadicke |
Name: |
| Ansbert Gadicke |
Title: |
| Managing Director |
By: |
| /s/ Ansbert Gadicke |
| |||||
Name: |
| Ansbert Gadicke |
| |||||
| ||||||||
By: |
| /s/ Luke Evnin |
| |||||
Name: |
| Luke Evnin |
| |||||
| ||||||||
By: |
| /s/ Todd Foley |
| |||||
Name: |
| Todd Foley |
| |||||
EXHIBIT 99.2
The Reporting Persons sold the following Common Stock in the open market in the sixty days preceding the date of this filing:
Sold by | Sold by AM | Sold by | Sold by AM | ||||
Date of | Sold by | BV | BV2014 | Sold by | BV | BV2018 | |
Sale | Price Range Ave. Price | BV 2014 | 2014(B) | LLC | BV 2018 | 2018(B) | LLC |
08/24/26 | $7.0852-$7.58 $ 7.34 | 9,819 | 655 | 338 | 10,077 | 535 | 199 |
08/25/26 | $7.28-$7.6421 $ 7.54 | 12,043 | 803 | 415 | 12,360 | 657 | 244 |
08/26/26 | $6.97-$7.55 $ 7.06 | 6,615 | 441 | 228 | 6 790 | 361 | 134 |
08/27/26 | $6.88-$7.37 $ 7.20 | 17,674 | 1,179 | 608 | 18,139 | 964 | 358 |
08/28/26 | $6.95-$7.24 $ 7.01 | 1,695 | 113 | 58 | 1,740 | 93 | 34 |
08/31/26 | $6.76-$7.1626 $ 6.99 | 20,097 | 1,341 | 692 | 20,626 | 1,096 | 407 |
09/01/26 | $6.80-$7.15 $ 7.06 | 13,208 | 881 | 455 | 13,556 | 720 | 268 |
09/02/26 | $6.9601-$7.3273 $ 7.19 | 11,412 | 761 | 393 | 11,712 | 622 | 231 |
09/03/26 | $7.0434-$7.405 $ 7.17 | 14,650 | 977 | 504 | 15,036 | 799 | 297 |
09/04/26 | $7.01-$7.16 $ 7.11 | 17,482 | 1,166 | 602 | 17,942 | 954 | 354 |
09/08/26 | $6.97-$7.70 $ 7.41 | 87,411 | 5,830 | 3,009 | 89,712 | 4,768 | 1,770 |
09/09/26 | $7.02-$7.54 $ 7.13 | 13,095 | 873 | 451 | 13,439 | 714 | 265 |
The Filing Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.